The primary focus at EGEN is overcoming the delivery barriers preventing the development of nucleic acid-based therapies and creating novel systems that can improve upon the delivery of existing therapeutic agents. EGEN has a proven track record utlizing polymers, liposomes, and active and passive targeting of nanoparticles for the treatment of cancer and has secured important intellectual property surrounding these platform technologies.
EGEN is currently developing the therapeutic applications of two platform technologies, TheraPlas™ for the delivery of DNA and TheraSilence™ for the delivery of RNAi. EGEN's lead candidate under the TheraPlas platform, EGEN-001, is being tested in a Phase 2 clinical trial for the treatment of ovarian cancer and a Phase 1 trial for the treatment of colorectal cancer. Additionally, EGEN-001 is being investigated in a pre-clincal setting for several other indications including glioblastoma and head and neck cancer. EGEN's TheraSilence platform is focused on therapeutically relevant delivery of RNAi. The lead candidate under investigation has been designed to posess a high level of chemical adaptibility which we are harnessing to both passively and actively target disease sites.
